This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lannett (LCI) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Neurocrine Biosciences (NBIX) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Neurocrine Biosciences (NBIX).
Why Neurocrine (NBIX) Could Be Positioned for a Surge
by Zacks Equity Research
Neurocrine (NBIX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Moving Average Crossover Alert: Neurocrine Biosciences
by Zacks Equity Research
Neurocrine Biosciences, Inc. (NBIX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
by Zacks Equity Research
Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
by Zacks Equity Research
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
Why Neurocrine (NBIX) Might be Well Poised for a Surge
by Zacks Equity Research
Neurocrine (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 54.17% and 14.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Neurocrine (NBIX) Ahead of Earnings?
by Zacks Equity Research
Neurocrine (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug
by Zacks Equity Research
The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.
CTLT or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 35.71% and -0.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Neurocrine Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Neurocrine Biosciences, Inc.
4 Defensive Stocks to Buy Amid Shutdown and Brexit
by Zacks Equity Research
Defensive equities could ride out market unpredictability.
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
by Zacks Equity Research
Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.
Do Options Traders Know Something About Neurocrine Biosciences (NBIX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.
Neurocrine (NBIX) Catches Eye: Stock Jumps 6.5%
by Zacks Equity Research
Neurocrine (NBIX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 8.33% and 0.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
by Zacks Equity Research
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.